Equities

Oxford Nanopore Technologies PLC

ONT:LSE

Oxford Nanopore Technologies PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)141.00
  • Today's Change-5.20 / -3.56%
  • Shares traded1.21m
  • 1 Year change5.22%
  • Beta1.1554
Data delayed at least 20 minutes, as of Feb 06 2026 16:43 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.

  • Revenue in GBP (TTM)204.71m
  • Net income in GBP-143.34m
  • Incorporated2005
  • Employees1.33k
  • Location
    Oxford Nanopore Technologies PLCOxford Science ParkGosling Building, Edmund Halley RoadOXFORD OX4 4DQUnited KingdomGBR
  • Websitehttps://www.nanoporetech.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Paul Hartmann AG2.11bn70.75m691.52m10.09k691.52m10.09k
Gerresheimer AG1.95bn20.27m769.33m13.54k769.33m13.54k
Eckert & Ziegler SE264.29m35.26m851.26m1.11k851.26m1.11k
ChemoMetec A/S57.29m20.57m873.48m172.00873.48m172.00
El En SpA-86.80bn-86.80bn993.61m1.42k993.61m1.42k
Vitrolife AB279.96m-408.02m1.00bn1.15k1.00bn1.15k
Medartis Holding AG223.79m-461.14k1.14bn1.16k1.14bn1.16k
SKAN Group AG314.50m15.32m1.19bn1.50k1.19bn1.50k
Draegerwerk AG & Co KGaA2.97bn104.93m1.26bn16.68k1.26bn16.68k
Oxford Nanopore Technologies PLC204.71m-143.34m1.36bn1.33k1.36bn1.33k
AddLife AB850.06m45.59m1.46bn2.30k1.46bn2.30k
Embla Medical hf682.12m61.21m1.50bn4.19k1.50bn4.19k
Elekta AB (publ)1.43bn23.77m1.66bn4.48k1.66bn4.48k
SCHOTT Pharma AG & Co KgaA856.06m127.13m1.86bn4.81k1.86bn4.81k
Data as of Feb 06 2026. Currency figures normalised to Oxford Nanopore Technologies PLC's reporting currency: UK Pound GBX

Institutional shareholders

21.43%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 10 Jun 202547.73m4.94%
Natixis Investment Managers International SAas of 01 Jan 202641.48m4.30%
Storebrand Asset Management ASas of 01 Jan 202635.29m3.65%
Lansdowne Partners (UK) LLPas of 29 Feb 202425.70m2.66%
Aberforth Partners LLPas of 01 Jan 202613.45m1.39%
Citibank (Switzerland) AGas of 01 Jan 202613.12m1.36%
ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Nov 20258.20m0.85%
T. Rowe Price Hong Kong Ltd.as of 30 Sep 20257.79m0.81%
The Vanguard Group, Inc.as of 01 Jan 20267.39m0.77%
Bessemer Investment Management LLCas of 01 Jan 20266.79m0.70%
More ▼
Data from 30 Sep 2025 - 02 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.